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Hispanic Caucasian (NHC) patients in a managed care plan.
METHODS: A retrospective claims database analysis was con-
ducted using eligibility, pharmacy, and medical claims data from
a large US health plan, supplemented by a linked database 
of socioeconomic characteristics (race, ethnicity, household
income). Patients 6–64 years newly treated with ADHD therapy
between January 1, 2000 and December 31, 2004, with contin-
uous enrollment for 6 months prior and 12 months following
the earliest ADHD prescription were selected. RESULTS: HIS
subjects (N = 2827) were younger (mean age 19.0 vs 21.6 years),
had shorter duration of continuous insurance coverage, and were
in lower income brackets compared to NHC subjects (N =
59,820) (p < 0.001). Anxiety and depression were more com-
monly diagnosed among NHC (16% and 24%) compared to HIS
subjects (13% and 20%). Though rates of single prescription
ﬁlling for ADHD medications were high in both groups (27%),
HIS subjects were less compliant with therapy compared to NHC
subjects. HIS status was a signiﬁcant predictor of total and
ADHD-related health care costs during the follow-up period,
controlling for patient age, index drug, insurance type, and geo-
graphic region. Among HIS, adjusted mean total costs were 21%
lower than among NHC ($3295 vs $4187, p < 0.001); ADHD-
related costs were 29% lower ($696 vs. $986, p < 0.001) for HIS
vs. NHC. HIS subjects had fewer physician ofﬁce and acute care
visits during follow-up. Within race/ethnic groups, increasing
income was associated with increased all cause, but decreased
ADHD-related cost and utilization. CONCLUSION: This study
indicates that total and ADHD-related health care costs are
lower among HIS patients with ADHD than in NHC patients,
with a greater difference for ADHD related costs than total costs.
HIS subjects were less persistent with ADHD therapy and used
fewer health care services compared to NHC subjects.
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OBJECTIVES: To proﬁle antipsychotic use among bipolar dis-
order patients, including antipsychotic type, duration of use,
gaps in therapy, and concurrent mood-stabilizer and antidepres-
sant therapy. METHODS: Bipolar disorder patients with at least
two antipsychotic prescriptions ﬁlled between January 1, 1999,
and December 31, 2001 were extracted from a Medicaid data-
base. Initiation of antipsychotic therapy was indicated by the
absence of claims for antipsychotic medication within 90 days
prior to the ﬁrst prescription. Duration of therapy was calculated
from the ﬁrst prescription ﬁll date to the end of 12 months
follow-up or discontinuation of antipsychotic therapy. Gaps
between reﬁlls were deﬁned as the number of days between the
depletion date and the ﬁll date. A treatment gap category was
calculated for each patient based on the longest continuous gap
between reﬁlls. Antipsychotic use was considered to be ﬁrst-line
treatment if there were no claims for mood-stabilizers in the 12
months before antipsychotic initiation. Prescription claims in the
12-month follow-up period were examined to classify treatments
as antipsychotic alone or combined with mood-stabilizer or anti-
depressant. RESULTS: Among 832 patients initiated on antipsy-
chotics, 75.4% were initiated on atypicals and 24.6% on
typicals. The average duration of therapy was 224.5 (±140.5)
days. In total, 58.9% of patients had gaps between reﬁlls exceed-
ing 30 days, and 22.7% had at least one gap exceeding 90 days.
The average duration of the longest gap was 61.2 (±70.3) days.
Antipsychotics were the ﬁrst-line treatment in 66.8% of patients.
During follow-up, 56.3% of patients used antipsychotics alone,
43.8% used combinations of antipsychotics and mood-stabiliz-
ers, and 73.7% used antipsychotics with antidepressants. CON-
CLUSION: Short duration of antipsychotic use and long gaps in
therapy indicate poor adherence to therapy in bipolar disorder
patients. About two-thirds of patients initiate antipsychotics
before mood-stabilizers. Concomitant use of a mood-stabilizer
or antidepressant with antipsychotic is highly prevalent.
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OBJECTIVES: To examine pharmacologic treatment patterns
for individuals diagnosed with Generalized Anxiety Disorder
(GAD) with comorbid depression and/or pain. METHODS:
Data were from PharMetrics Integrated Outcomes Database.
Patients aged 18–64 were selected if they had a diagnosis of GAD
(ICD9-CM: 30002) between January 2003 and June 2004, pre-
ceded by 6 months without GAD diagnosis, and continuous
enrollment during 6-month prior and 12-month after GAD diag-
nosis. Treatment regimens during the year after GAD diagnosis
were examined for six-classes of psychotropics (anxiolytics, 
antidepressants, anticonvulsants, noradrenergic agents, atypical
antipsychotics, and hypnotics). Comparisons were made for
patients with GAD only versus those with comorbid depression
and/or pain conditions. Poisson regressions controlling patient
demographic and clinical characteristics (including provider spe-
cialty and other comorbidities), were used to evaluate the impact
of depression and pain on GAD treatment patterns. RESULTS:
Of 36,435 patients (mean age 41.5 years, 67% female) included
in this analysis, 23.8% had GAD only, 15.5% GAD/depression,
32.8% GAD/pain, and 28.0% GAD/depression/pain. For
patients with GAD/depression/pain, 48.5% received anxiolytics,
15.7% anticonvulsants, and 15.4% hypnotics, 44.2% received
≥3 and 11.9% ≥6 of different drugs of psychotropics, which 
were all signiﬁcantly higher than other groups. Compared to
GAD/depression patients, GAD/pain received signiﬁcantly more
analgesics (46.2% vs. 21.3%, p < 0.001) and muscle relaxants
(14.5% vs. 3.2%, p < 0.001), and less antidepressants (44.6%
vs. 71.5%, p < 0.001). Regression results from Poisson model
revealed that patients with GAD/depression/pain received 0.67
more classes of and 1.28 more number of psychotropic drugs (p
< 0.001 for both) when compared to GAD only. Similar results
were also observed for patients with GAD/depression and for
those with GAD/pain though to a lesser extent. CONCLUSION:
The ﬁndings suggest that there is a high comorbid prevalence of
depression and pain with GAD. Associated with this high comor-
bidity, complex patterns of polypharmacy are common in the
treatment of GAD.
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OBJECTIVES: To determine factors associated with initiation of
atomoxetine (ATX), stimulants (STIM), or long-acting stimu-
